BiotechTube
Cryosa

Cryosa

Maple Grove, United States· Est.
cryosa.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Cryosa is a privately held, clinical-stage biotech company pioneering a non-invasive treatment for obstructive sleep apnea (OSA) using a proprietary cryotherapy platform. Founded in 2015 and based in Maple Grove, Minnesota, the company is advancing its lead program through a U.S. pilot study (ARCTIC-3), having secured significant venture funding to date. Cryosa aims to address the large unmet need in the OSA market, where current standard-of-care options like CPAP machines suffer from poor patient tolerance and adherence.

Obstructive Sleep ApneaRespiratory Sleep Disorders

Technology Platform

Proprietary cryotherapy (controlled cooling) platform for selective adipose cryolysis to reduce tissue volume in the upper airway via an incisionless procedure.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The primary opportunity lies in addressing the massive unmet need in the OSA market, where poor CPAP adherence creates demand for effective alternatives.
A successful, minimally invasive, in-office procedure could achieve rapid adoption by sleep specialists and ENT surgeons, capturing a significant portion of the CPAP-intolerant patient population.

Risk Factors

Key risks include clinical trial failure, regulatory hurdles for a novel device, and challenges in achieving commercial reimbursement.
As a single-asset, pre-revenue company, Cryosa is also highly dependent on the success of its lead program and its ability to secure additional funding.

Competitive Landscape

Cryosa competes with CPAP (the dominant standard of care), invasive surgeries (UPPP, MMA), and hypoglossal nerve stimulators (e.g., Inspire Medical Systems). Its differentiation is a minimally invasive, tissue-reducing procedure that is neither an external mask nor a permanent implant, targeting a potentially broader patient population than nerve stimulators.

More companies in Digital Health & Biotech SaaS →More companies in United States →